Skip to main content
. 2022 Mar;11(3):569–579. doi: 10.21037/tcr-22-344

Figure 6.

Figure 6

Overall incidence of adverse reactions in RRMM patients treated with CAR-T therapy (10-14,16-19). CI, confidence interval; RRMM, relapsed or refractory multiple myeloma; CAR, chimeric antigen receptor.